Pfizer’s gene therapy for Duchenne muscular dystrophy fails in Phase 3 trial

Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed to slow the disease’s progression in a Phase 3 trial.

This is now the second large, randomized, placebo-controlled trial of a Duchenne gene therapy to fail to reach its primary endpoint, a composite scale of muscle function designed specifically for the rare disease. A similar study of a Sarepta gene therapy failed last year, although the company pointed to secondary measures as evidence that its treatment was still slowing the fatal, muscle-wasting condition.

advertisement

Pfizer said that in its study, which enrolled 99 boys between ages 4 and 7 and followed them for a year, its gene therapy did not show any difference on those key secondary endpoints.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe